摘要目的:探讨舒利迭治疗稳定期慢性阻塞性肺疾病（COPD）患者的效果及对高分辨率CT（HRCT）参数的影响。方法:选取本院收治的140例稳定期COPD患者作为研究对象，根据入院顺序将患者分为联合组和对照组各70例，两组均给予噻托溴铵粉治疗，联合组同时给予舒利迭治疗，两组患者均治疗3个月。对比治疗前后的用力肺活量（FVC）、第一秒用力肺活量（FEV 1）、肺一氧化碳弥散量（DLCO）、HRCT参数的低衰减区域占全非体积百分比（LAA%）、2倍气道壁厚度与气道直径比（2T/D）、管壁面积占总横截面积比（WA）、临床疗效。 结果:治疗前，联合组和对照组的FVC、FEV 1、FEV 1/FVC、DLCO值差异均无统计学意义（均 P>0.05）；治疗后，联合组的FVC、FEV1、DLCO值均高于对照组（均 P<0.05）。治疗前，联合组和对照组的LAA%、2T/D、WA值差异均无统计学意义（均 P>0.05）；治疗后，联合组的LAA%、2T/D、WA值低于对照组（均 P<0.05）。治疗后，联合组的疗效分布优于对照组（ P<0.05）。治疗后，联合组的不良反应发生率8.96%与对照组的5.97%比较，差异无统计学意义（ P>0.05）。 结论:噻托溴铵粉联合舒利迭治疗稳定期COPD对于改善肺功能、气流受限具有积极作用，从而提高临床疗效。

abstractsObjective:To investigate the effect of Seretide in the treatment of patients with stable COPD and its effect on HRCT parameters.Methods:140 patients with stable COPD admitted in our hospital were selected as the research objects, and were divided into combined group and control group with 70 cases in each group according to the order of admission. The patients in both groups were treated with tiotropium bromide powder, and the patients in the combined group were treated with Seretide on the basis for 3 months. The parameters of FVC, FEV 1, DLCO, and LAA%, 2T/D, WA of HRCT parameters before and after treatment, and clinical efficacy were compared. Results:Before treatment, there were no statistically significant differences in FVC, FEV 1, FEV 1/FVC, and DLCO values between the combined group and the control group (all P>0.05); after treatment, the FVC, FEV 1, and DLCO values of the combined group were higher than those of the control group (all P<0.05). Before treatment, there were no statistically significant differences in LAA%, 2T/D, and WA values between the combined group and the control group (all P>0.05); after treatment, the LAA%, 2T/D, and WA values of the combined group were lower than those of the control group (all P<0.05). After treatment, the efficacy distribution of the combined group was better than that of the control group ( P<0.05). After treatment, the incidence of adverse reactions in the combined group was 8.96%, without statistically significant difference compared with 5.97% in the control group ( P>0.05). Conclusion:Tiotropium bromide powder combined with Seretide in the treatment of stable COPD has a positive effect on improving lung function and airflow restriction, thereby improving clinical efficacy.